DUBLIN--(BUSINESS WIRE)--The "Prenatal Diagnostics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global Prenatal Diagnostics Market to Reach $9.3 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Prenatal Diagnostics, estimated at US$4 Billion in the year 2020, is projected to reach a revised size of US$9.3 Billion by 2027, growing at a CAGR of 12.9% over the analysis period 2020-2027. Non-Invasive, one of the segments analyzed in the report, is projected to record 16% CAGR and reach US$6.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Invasive segment is readjusted to a revised 7.5% CAGR for the next 7-year period.
The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 17.2% CAGR
The Prenatal Diagnostics market in the U.S. is estimated at US$1.1 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2027 trailing a CAGR of 17.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.7% and 11.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10% CAGR.
Select Competitors (Total 43 Featured) -
- ANGLE Plc
- Berry Genomics Co. Ltd.
- BGI Genomics
- F. Hoffmann-La Roche Ltd.
- Hologic Inc.
- Illumina Inc.
- Laboratory Corporation of America Holdings
- Lifecodexx AG
- Natera Inc.
- Quest Diagnostics Inc.
- Ravgen Inc.
- Sequenom Inc.
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Non-Invasive Prenatal Testing (NIPT) Transforms Prenatal Testing Landscape
- Major Factors Influencing Penetration of NIPT
- NIPT Eliminates Risks & Uncertainty of Conventional Procedures
- Replacing Screening Tests - A More Conceivable Change through NIPT
- Diversity in NIPT Usage on the Cards
- Benefits Outweigh Snags in NIPT Tests
- Whole Genome Sequencing Technology in NIPT
- DNA - More Ideal Target for NIPT Analysis than Whole Cells
- Conventional Invasive Techniques Loose Sheen
- Chromosomal Abnormalities Lead the Prenatal Testing Space
- Chromosomal Abnormalities - A Substantial Economic Burden
- List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
- Significant Opportunities in Down's Syndrome Testing
- List of Select Screening Tests Available for T21 Screening and Confirmation
- Beyond Down's Syndrome - Need to Test Additional Targets Crucial
- ACOG and ACGM Recommendations Boost Demand for Prenatal CF Testing
- Prenatal Testing Crucial to Detect Risk of Huntington's Disease
- Increasing Congenital Disorder Incidence - Key Driver for Prenatal Diagnostics
- Prenatal Testing - Effective Way of Alleviating Syphilis Related Deaths and Stillbirths
- Molecular Diagnostics Widen Scope & Span of Prenatal Testing
- NGS & MPS - Enabling Shorter Time to Test Results
- Microarray-Based Prenatal Testing Gathers Steam
- Sequencing in Prenatal Testing - A Potential High Growth Market
- Ultrasound - An Indispensable Combination with Blood Based Screening Tests
- New Sub-Targets on the Anvil for Ultrasound-Based Screening
- Counseling - An Imperative Measure Before and After Prenatal Testing
- Role of Prenatal Testing in Managing Preterm Births
- Lower Sensitivity & Specificity of Existing Tests - A Case for New Tests on the Anvil
- High Sensitivity Serum Tests May Not Have Many Takers
- Ballooning Global Female Population Offers Increased Growth Opportunities
- Issues & Challenges
- Prenatal Diagnostics: Treading Sensitive Ethical Issues
- Controversy Related to "Incidental Findings" of Prenatal Tests
- Opposition to NIPT Technique - A Significant Hurdle to Adoption
- Unresolved Issues Hamper Widespread Testing for Monogenetic Disease
- Dearth of Genetic Counselors - A Major Hurdle for Genetic Testing
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
IV. COMPETITION
Companies Mentioned
- ANGLE Plc
- Berry Genomics Co. Ltd.
- BGI Genomics
- F. Hoffmann-La Roche Ltd.
- Hologic Inc.
- Illumina Inc.
- Laboratory Corporation of America Holdings
- Lifecodexx AG
- Natera Inc.
- Quest Diagnostics Inc.
- Ravgen Inc.
- Sequenom Inc.
For more information about this report visit https://www.researchandmarkets.com/r/c0qvsr
